Biotech Morning

IssuesPast Issues Subscribe

Biotech Morning

IssuesPast Issues Subscribe

Biotech News

Original reporting and analysis on the stories shaping biotech.

The Senator Who Bet His Life on a Drug That Didn't Exist Two Years Ago

Clinical & Regulatory6 min read

The Senator Who Bet His Life on a Drug That Didn't Exist Two Years Ago

Former Senator Ben Sasse enrolled in a Revolution Medicines trial for a drug that scientists said couldn't exist, targeting the "undruggable" protein behind 90% of pancreatic cancers. The Phase 3 data that just dropped shows patients living nearly twice as long as those on chemo.

Apr 15, 2026Read article

Latest

Astellas Paid $102M for a Stem Cell Bet. Now It's Walking Away.

Deals & M&A4 min read

Astellas Paid $102M for a Stem Cell Bet. Now It's Walking Away.

Astellas Pharma is shuttering its Seattle stem cell unit and cutting 55 jobs, eight years after paying $102.5 million for the technology. The move raises fresh questions about whether regenerative medicine can ever close the gap between scientific promise and commercial reality.

The App That Treats Schizophrenia Just Lost 27% of Its Team

Deals & M&A4 min read

The App That Treats Schizophrenia Just Lost 27% of Its Team

Page 1 of 16Older

Get tomorrow's biotech intelligence before your competitors.

Join thousands of biotech professionals who start their day with our free, daily briefing.

Email address

Past Issues•News•Privacy Policy•Terms•Contact

© 2026 Biotech Morning. All rights reserved.

Click Therapeutics raised $50 million and then cut 27% of its staff in the same week. The company is betting it can succeed where Pear Therapeutics spectacularly failed: turning a prescription app into a real commercial product.

Apr 15, 2026

The FDA Just Sent 2,200 Companies a Very Uncomfortable Reminder

Clinical & Regulatory4 min read

The FDA Just Sent 2,200 Companies a Very Uncomfortable Reminder

The FDA just contacted over 2,200 companies about 3,000 unreported clinical trials, and this time it's not just a friendly reminder. Nearly a third of trials that should have results on ClinicalTrials.gov are completely missing, and the agency's patience is running out.

The $100M Bet on Drugs That Work Like Superglue

Funding & Financings4 min read

The $100M Bet on Drugs That Work Like Superglue

Neomorph just raised $100M to advance a drug that works nothing like traditional medicine: instead of blocking cancer proteins, it glues them to the cell's trash compactor. With Deerfield, Regeneron Ventures, and three Big Pharma partnerships already in hand, the real test starts now.

The $528M Bet That Obesity Drugs Still Have Room for One More

Funding & Financings4 min read

The $528M Bet That Obesity Drugs Still Have Room for One More

A company that didn't exist two years ago wants to raise $528.5 million in one of the biggest biotech IPOs of 2026. Kailera Therapeutics is betting the obesity drug market is big enough for one more GLP-1 player, and Bain Capital is putting $225 million where its mouth is.

Big Pharma's Immunology Spring Cleaning Has Begun

Clinical & Regulatory4 min read

Big Pharma's Immunology Spring Cleaning Has Begun

Amgen and Boehringer Ingelheim both killed immunology programs on the same day, citing slim odds of success. The terminations were tiny, but the signal they send about pharma's tightening standards is anything but.

The Protein Company That Tripled Revenue Wants a Billion-Dollar Valuation

Funding & Financings4 min read

The Protein Company That Tripled Revenue Wants a Billion-Dollar Valuation

A protein detection company you've probably never heard of just tripled its revenue and is asking Wall Street for a billion-dollar valuation. Alamar Biosciences is betting that proteins, not just DNA, hold the key to finding diseases early.

AbbVie's $745M Bet That Pain Relief Doesn't Need Opioids

Deals & M&A4 min read

AbbVie's $745M Bet That Pain Relief Doesn't Need Opioids

AbbVie just licensed two early-stage, non-opioid pain drugs from a Chinese pharma company most people have never heard of, in a deal worth up to $745 million. It's a small upfront bet with massive implications for AbbVie's post-Humira future and the booming China-to-West licensing pipeline.

Lilly's $300M Bet on a Biotech That Doesn't Even Have a Drug in Humans Yet

Deals & M&A6 min read

Lilly's $300M Bet on a Biotech That Doesn't Even Have a Drug in Humans Yet

Eli Lilly just dropped up to $300 million on a two-year-old company with zero drugs in human testing. CrossBridge Bio's dual-payload ADC technology has Big Pharma salivating, and this deal says a lot about where the antibody-drug conjugate arms race is headed.

GSK's $31 Billion Bet Starts With a Cancer Most Companies Won't Touch

Clinical & Regulatory4 min read

GSK's $31 Billion Bet Starts With a Cancer Most Companies Won't Touch

GSK is launching five Phase 3 trials simultaneously for a gynecologic cancer ADC that posted a 62% response rate in heavily pretreated ovarian cancer patients. It's the company's boldest oncology bet in years, and it's targeting a space the biggest ADC players have mostly ignored.

Big Pharma's Immunology Spring Cleaning Has Begun

Clinical & Regulatory4 min read

Big Pharma's Immunology Spring Cleaning Has Begun

Boehringer Ingelheim and Amgen both axed immunology programs within weeks of each other, one for futility and one for safety. They're not retreating from the space; they're raising the bar for what deserves to survive.

Regeneron Just Crashed the Hottest Party in Oncology

Deals & M&A4 min read

Regeneron Just Crashed the Hottest Party in Oncology

Regeneron, the antibody powerhouse, just made a surprise $2.1 billion bet on radioactive cancer drugs through a deal with Telix Pharmaceuticals. It's the latest sign that radiopharmaceuticals have gone from niche curiosity to the hottest arms race in oncology.

The Cancer That Kills Fast Just Met a Drug That Moves Faster

Clinical & Regulatory5 min read

The Cancer That Kills Fast Just Met a Drug That Moves Faster

The FDA just fast-tracked a new guided-missile cancer drug for small cell lung cancer, one of oncology's most brutal diseases. With a 48% response rate where standard options barely move the needle, Daiichi Sankyo and Merck's $4 billion bet might be about to pay off.

The $10K Cancer Therapy That Just Passed Its Biggest Test

Clinical & Regulatory4 min read

The $10K Cancer Therapy That Just Passed Its Biggest Test

Allogene's off-the-shelf CAR-T therapy cleared residual lymphoma cells at 3.5 times the rate of observation alone, with zero serious side effects. If durability data holds, the $10K-per-dose treatment could upend the $400K autologous CAR-T model entirely.

The Eye Cancer That Finally Got a Real Drug

Clinical & Regulatory4 min read

The Eye Cancer That Finally Got a Real Drug

IDEAYA Biosciences just dropped uveal melanoma trial data that more than doubled progression-free survival in patients who had almost no treatment options. Wall Street loved it, an FDA filing is coming, and a half-billion-dollar partnership is fueling what comes next.

Two Biotechs Just Rang the IPO Bell on the Same Day

Funding & Financings5 min read

Two Biotechs Just Rang the IPO Bell on the Same Day

Seaport Therapeutics and Hemab Therapeutics both filed $100 million IPOs on the exact same day, targeting depression and rare bleeding disorders respectively. Their simultaneous filings say a lot about where the biotech IPO market stands in Q2 2026.

The Protein That Stumped Cancer Researchers for 40 Years Just Lost

Clinical & Regulatory5 min read

The Protein That Stumped Cancer Researchers for 40 Years Just Lost

For 40 years, the RAS protein was cancer research's most infamous failure: too smooth, too stubborn, too "undruggable." Revolution Medicines just posted Phase 3 results that nearly doubled survival in pancreatic cancer patients, and the implications go far beyond one drug.

Gilead Just Spent $13 Billion in Six Weeks. What Do They Know?

Deals & M&A5 min read

Gilead Just Spent $13 Billion in Six Weeks. What Do They Know?

Gilead Sciences just closed its third acquisition in six weeks, bringing its recent M&A tab to nearly $13 billion. The latest buy: a German ADC biotech that could reshape how cancer drugs find their targets.

Big Pharma Can't Stop Shopping in China

Deals & M&A4 min read

Big Pharma Can't Stop Shopping in China

Western pharma companies poured $52 billion into Chinese biotech licensing deals in just the first two months of 2026, nearly matching all of 2024 in eight weeks. The shopping spree signals something bigger than bargain hunting: a fundamental power shift in where the world's best drugs are being invented.

The Lung Disease Bet That's Banking on a $4 Billion Market Nobody's Cracked

Funding & Financings4 min read

The Lung Disease Bet That's Banking on a $4 Billion Market Nobody's Cracked

Avalyn Pharma wants to take two blockbuster lung disease drugs and reinvent how patients receive them. The company just filed for a $100 million IPO, betting that inhaling these medications beats swallowing them.

The $110M Bet That CAR-T Can Finally Crack Solid Tumors

Funding & Financings4 min read

The $110M Bet That CAR-T Can Finally Crack Solid Tumors

A Shanghai biotech just raised $110 million to chase something nobody has achieved: the first CAR-T cell therapy approved for solid tumors. Oricell's early liver cancer data is turning heads, and the IPO clock is ticking.